These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 30300040)

  • 1. Advances and challenges in recombinant Mycobacterium bovis BCG-based HIV vaccine development: lessons learned.
    Kilpeläinen A; Maya-Hoyos M; Saubí N; Soto CY; Joseph Munne J
    Expert Rev Vaccines; 2018 Nov; 17(11):1005-1020. PubMed ID: 30300040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical development of BCG.HIVA
    Mahant A; Saubi N; Eto Y; Guitart N; Gatell JM; Hanke T; Joseph J
    Hum Vaccin Immunother; 2017 Aug; 13(8):1798-1810. PubMed ID: 28426273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors.
    Hopkins R; Bridgeman A; Bourne C; Mbewe-Mvula A; Sadoff JC; Both GW; Joseph J; Fulkerson J; Hanke T
    Eur J Immunol; 2011 Dec; 41(12):3542-52. PubMed ID: 21932450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine.
    Kim BJ; Kim BR; Kook YH; Kim BJ
    Front Immunol; 2018; 9():643. PubMed ID: 29636755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice.
    Kilpeläinen A; Saubi N; Guitart N; Moyo N; Wee EG; Ravi K; Hanke T; Joseph J
    Front Immunol; 2019; 10():923. PubMed ID: 31156614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells.
    Chapman R; Shephard E; Stutz H; Douglass N; Sambandamurthy V; Garcia I; Ryffel B; Jacobs W; Williamson AL
    PLoS One; 2012; 7(3):e32769. PubMed ID: 22479338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined intrarectal/intradermal inoculation of recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces enhanced immune responses against the inserted HIV-1 V3 antigen.
    Kawahara M; Matsuo K; Nakasone T; Hiroi T; Kiyono H; Matsumoto S; Yamada T; Yamamoto N; Honda M
    Vaccine; 2002 Dec; 21(3-4):158-66. PubMed ID: 12450689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant Mycobacterium bovis bacillus Calmette-Guerin elicits human immunodeficiency virus type 1 envelope-specific T lymphocytes at mucosal sites.
    Yu JS; Peacock JW; Jacobs WR; Frothingham R; Letvin NL; Liao HX; Haynes BF
    Clin Vaccine Immunol; 2007 Jul; 14(7):886-93. PubMed ID: 17507541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG.
    Saubi N; Mbewe-Mvula A; Gea-Mallorqui E; Rosario M; Gatell JM; Hanke T; Joseph J
    PLoS One; 2012; 7(8):e42559. PubMed ID: 22927933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
    Yuan X; Teng X; Jing Y; Ma J; Tian M; Yu Q; Zhou L; Wang R; Wang W; Li L; Fan X
    Appl Microbiol Biotechnol; 2015 Dec; 99(24):10587-95. PubMed ID: 26363555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of BCG as a live recombinant vector system: potential use as an HIV vaccine.
    Fuerst TR; Stover CK; de la Cruz VF
    Biotechnol Ther; 1991; 2(1-2):159-78. PubMed ID: 1845119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines.
    Aldovini A; Young RA
    Nature; 1991 Jun; 351(6326):479-82. PubMed ID: 2046750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals.
    Honda M; Matsuo K; Nakasone T; Okamoto Y; Yoshizaki H; Kitamura K; Sugiura W; Watanabe K; Fukushima Y; Haga S; Katsura Y; Tasaka H; Komuro K; Yamada T; Asano T; Yamazaki A; Yamazaki S
    Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10693-7. PubMed ID: 7479867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells.
    Venkataswamy MM; Ng TW; Kharkwal SS; Carreño LJ; Johnson AJ; Kunnath-Velayudhan S; Liu Z; Bittman R; Jervis PJ; Cox LR; Besra GS; Wen X; Yuan W; Tsuji M; Li X; Ho DD; Chan J; Lee S; Frothingham R; Haynes BF; Panas MW; Gillard GO; Sixsmith JD; Korioth-Schmitz B; Schmitz JE; Larsen MH; Jacobs WR; Porcelli SA
    PLoS One; 2014; 9(9):e108383. PubMed ID: 25255287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG.
    Tullius MV; Harth G; Maslesa-Galic S; Dillon BJ; Horwitz MA
    Infect Immun; 2008 Nov; 76(11):5200-14. PubMed ID: 18725418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and protective efficacy conferred by a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing interleukin-12p70 of human cytokine and Ag85A of Mycobacterium tuberculosis fusion protein.
    Deng YH; He HY; Zhang FJ
    Scand J Immunol; 2013 Dec; 78(6):497-506. PubMed ID: 24283772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding.
    Im EJ; Saubi N; Virgili G; Sander C; Teoh D; Gatell JM; McShane H; Joseph J; Hanke T
    J Virol; 2007 Sep; 81(17):9408-18. PubMed ID: 17596303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycobacterial codon optimization enhances antigen expression and virus-specific immune responses in recombinant Mycobacterium bovis bacille Calmette-Guérin expressing human immunodeficiency virus type 1 Gag.
    Kanekiyo M; Matsuo K; Hamatake M; Hamano T; Ohsu T; Matsumoto S; Yamada T; Yamazaki S; Hasegawa A; Yamamoto N; Honda M
    J Virol; 2005 Jul; 79(14):8716-23. PubMed ID: 15994765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges.
    Joseph J; Saubi N; Pezzat E; Gatell JM
    Expert Rev Vaccines; 2006 Dec; 5(6):827-38. PubMed ID: 17184220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.